Cost-effectiveness analysis of posaconazole versus voriconazole in the empiric or diagnostic-driven treatment of invasive mould diseases in immunocompromised patients
10.12206/j.issn.2097-2024.202401050
- VernacularTitle:泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析
- Author:
Xiaoping SHI
1
;
Qianzhou LYU
1
;
Xiaoyu LI
1
;
Qing XU
1
Author Information
1. Department of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai 200032 China.
- Publication Type:Originalarticles
- Keywords:
posaconazole;
voriconazole;
invasive mould diseases;
cost-effectiveness analyses;
decision-tree model
- From:
Journal of Pharmaceutical Practice and Service
2024;42(12):512-519
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cost-effectiveness of posaconazole compared with voriconazole in the empiric or diagnostic-driven treatment of invasive mould diseases （IMD） in immunocompromised patients from the perspective of Chinese health system. Methods A decision tree model was constructed based on a phase Ⅲ clinical trial and other publicly available data to evaluate the incremental cost-effectiveness ratio （ICER） of posaconazole versus voriconazole. One-way sensitivity analysis, probability sensitivity analysis, and scenario analysis were conducted. Results The results of base-case analysis indicated that, at a willingness-to-pay （WTP） threshold of 3 times Chinese GDP per capita, posaconazole gained 0.0327 quality-adjusted life years （QALYs） with the cost savings of CNY 1 711.24, demonstrating a clear cost-effectiveness advantage. Sensitivity analysis revealed that the cost of voriconazole and posaconazole significantly influenced the ICER. Under different WTP thresholds, posaconazole consistently maintained its economic advantage over voriconazole. Scenario analysis showed that the incidence of mucormycosis did not impact the results, but a price reduction in voriconazole could change result. Conclusion In the empiric or diagnostic-driven treatment of IMD in immunocompromised patients, posaconazole was both an effective and economically viable choice when compared to voriconazole.
